336 related articles for article (PubMed ID: 27085747)
41. Prostate Cancer: Has Patience Paid Off?
Jarrett TW
Can J Urol; 2017 Aug; 24(4):8871. PubMed ID: 28832301
[No Abstract] [Full Text] [Related]
42. The effect of lowering the prostate-specific antigen normal cutoff on referral rates to urology.
Shenker BS; Stern J
J Am Board Fam Med; 2012; 25(6):927-9. PubMed ID: 23136335
[TBL] [Abstract][Full Text] [Related]
43. Re: optimization of PSA screening policies: a comparison of the patient and societal perspectives.
Penson DF
J Urol; 2013 Feb; 189(2):529-30. PubMed ID: 23312159
[No Abstract] [Full Text] [Related]
44. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
Makovey I; Stephenson AJ; Haywood S
Curr Urol Rep; 2013 Jun; 14(3):168-73. PubMed ID: 23568623
[TBL] [Abstract][Full Text] [Related]
45. Screening for Prostate Cancer.
Jin J
JAMA; 2018 May; 319(18):1946. PubMed ID: 29801013
[No Abstract] [Full Text] [Related]
46. Screening for Prostate Cancer: Recommendation Statement.
Am Fam Physician; 2018 Oct; 98(8):Online. PubMed ID: 30277733
[No Abstract] [Full Text] [Related]
47. Early detection of prostate cancer.
Taneja SS
Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
[No Abstract] [Full Text] [Related]
48. Can we stop ordering prostate-specific antigen screening tests?
Katz MH
JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
[No Abstract] [Full Text] [Related]
49. Lung cancer screening gets risk-specific.
Peres J
J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
[No Abstract] [Full Text] [Related]
50. Landmarks in prostate cancer screening.
Schröder FH
BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
[TBL] [Abstract][Full Text] [Related]
51. Screening for Prostate Cancer.
Wolff T; Jadotte YJ
Am Fam Physician; 2018 Oct; 98(8):537-538. PubMed ID: 30277736
[No Abstract] [Full Text] [Related]
52. PSA testing and early management of test-detected prostate cancer--consensus at last.
Lawrentschuk N
BJU Int; 2016 Apr; 117 Suppl 4():5-6. PubMed ID: 27094969
[No Abstract] [Full Text] [Related]
53. Prostate cancer: what is the right message?
Glina S; Pasternak J
Einstein (Sao Paulo); 2015; 13(4):7-8. PubMed ID: 26761546
[No Abstract] [Full Text] [Related]
54. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
;
Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
[TBL] [Abstract][Full Text] [Related]
55. Should you get a prostate screening? New evidence shows screenings are down across the country.
Harv Health Lett; 2014 Jul; 39(9):6. PubMed ID: 25314734
[No Abstract] [Full Text] [Related]
56. The dilemmas of prostate cancer screening.
Hugosson J; Carlsson SV
Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
[No Abstract] [Full Text] [Related]
57. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
Welch HG; Albertsen PC
N Engl J Med; 2020 Apr; 382(16):1557-1563. PubMed ID: 32294352
[No Abstract] [Full Text] [Related]
58. Prostate cancer: measuring PSA.
Pezaro C; Woo HH; Davis ID
Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
[TBL] [Abstract][Full Text] [Related]
59. To screen or not to screen for prostate cancer?
Lancet; 2012 Jun; 379(9831):2024. PubMed ID: 22656872
[No Abstract] [Full Text] [Related]
60. The Roles of Providers and Patients in the Overuse of Prostate-Specific Antigen Screening in the United States.
Guo F; He D
Ann Intern Med; 2015 Oct; 163(8):650-1. PubMed ID: 26502132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
